Cargando…
Actos Now for the prevention of diabetes (ACT NOW) study
BACKGROUND: Impaired glucose tolerance (IGT) is a prediabetic state. If IGT can be prevented from progressing to overt diabetes, hyperglycemia-related complications can be avoided. The purpose of the present study was to examine whether pioglitazone (ACTOS(®)) can prevent progression of IGT to type...
Autores principales: | DeFronzo, Ralph A, Banerji, MaryAnn, Bray, George A, Buchanan, Thomas A, Clement, Stephen, Henry, Robert R, Kitabchi, Abbas E, Mudaliar, Sunder, Musi, Nicolas, Ratner, Robert, Reaven, Peter D, Schwenke, Dawn, Stentz, Frankie B, Tripathy, Devjit |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725044/ https://www.ncbi.nlm.nih.gov/pubmed/19640291 http://dx.doi.org/10.1186/1472-6823-9-17 |
Ejemplares similares
-
Prevention of Diabetes With Pioglitazone in ACT NOW: Physiologic Correlates
por: DeFronzo, Ralph A., et al.
Publicado: (2013) -
Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW
por: Tripathy, Devjit, et al.
Publicado: (2014) -
Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk
por: DeFronzo, Ralph A., et al.
Publicado: (2013) -
Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance
por: Espinoza, Sara E., et al.
Publicado: (2016) -
Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2009)